Abstract. This guidance on the creation of evidence-linked guidelines was issued to the COIN Specialty Working Groups charged in 1995 with producing clinical guidelines for breast, colorectral, lung, prostate and testicular cancer and generic guidelines for the delivery of radio-and chemotherapy on behalf of the Faculty of Clinical Oncology of The Royal College of Radiologists and the Joint Council for Clinical Oncology. The first of these guidelines, for lung cancer, is published elsewhere in this issue.
Background
Evidence-based clinical practice guideline creation for the COIN project commenced in 1995 with the formation of specialty working groups (SWGs) for lung, breast, prostate and colorectal cancer, and for radiotherapy and chemotherapy. The guidelines creation process for these and some further areas is now complete and the final versions will be published in future issues of Clinical Oncology. After publication they will also be downloadable from: http:// www.rcr.ac.uk/enquiries/coin/coin_home.html
The details of the specific methods applied by each SWG are contained in the individual guideline documents. Each group used slightly different approaches but initially all groups were provided with this guidance document. Because it forms the initiating document for the guidelines creation process utilized by COIN SWGs, it is reproduced here.
There is one note of caution: the following represented a distillate of the state of the art in 1995; guidelines and evidence based-medicine have moved on since then and readers contemplating the development of new guidelines should consult current sources for guidance. They should also be aware that clinical practice guideline creation is an arduous and time-consuming activity!
Introduction

Evidence of widespread medical practice variation (MPV), defined as variations in decisions by
different doctors when presented with the same or similar patients, in many areas of medicine including clinical oncology [1] [2] [3] is causing increasing concern for clinical and economic reasons. There is broad agreement that clinical decisions should be informed by the best scientific evidence available but this does not appear always to be the case [4] .
2.2.
Scientific evidence may vary in quality either because of methodological difficulties or because of the conduct of experimental work. In oncology, only data from randomized controlled clinical trials can determine if there is a survival benefit resulting from a specific treatment. Often individual trials are too small to demonstrate it and statistical significance can only be achieved by pooling data from many trials. The best method of pooling data is the systematic overview or meta-analysis particularly where all data, both published and unpublished, are sought [5] .
2.3.
It is evident that there is a hierarchy of confidence levels that can be placed on data and the Agency for Health Care Policy and Research of the US Institute of Medicine (AHCPR) have arranged them as given in Tables 1 and 2 [6]: 2.4. Most existing guidelines are either based on literature reviews with their potential attendant biases or are consensus guidelines from consensus panels or expert committees. From Table 1 it becomes clear that, in the future, clinicians will need to admit that the scientific evidence on which they base their decisions is often quite lightweight.
2.5.
Common sense requires that an individual doctor's clinical judgement needs to take more into account when managing individual patients than just the scientific evidence. For example, the patient's wishes or comorbidities have to be allowed for and informed value judgements must be permitted since individuals will weigh the clinical cost of treatment versus potential outcomes differently.
2.6.
If evidence-linked medicine is to remain credible the 'grey zones' of clinical practice must be acknowledged [7] . There may be insufficient data available to guide practice. With increasing numbers of interventions there is an increased number of possible combinations. Since the individual interventions are usually studied in isolation it is not often known whether the outcomes from various possible combinations are likely to differ. Formal decision analysis can be a useful tool for comparing complex clinical strategies where hard data are available and few assumptions are made in constructing the model; unfortunately, this is rarely the case.
2.7.
Guidelines, therefore, do not obviate the need for good clinical practice and good communication skills. Doctors must resist attempts to turn them into technicians and remain carers practising the art of medicine, but with due regard to good solid evidence of efficacy and effectiveness.
2.8.
Evidence-based guidelines can be approached in a number of ways. In continental Europe and the USA, the first step is commonly a literature review followed by an attempt to deduce the 'best' treatment approach, culminating in the authoring of guidelines. This approach has one advantage: it suits collaborative efforts because the literature review can stand independently of guidelines and separate approaches to guideline writing can follow. However, it has two disadvantages: first the risk of bias, both in terms of selection of the literature and in weighting the evidence; and secondly, the tendency to make abstract recommendations rather than to address the problems of clinical decision making. For clinicians, perhaps the most important endpoint for assessing the quality of guidelines will be their practical credibility.
Method
3.1.
In order for clinical practice guidelines (CPG) to be of practical value and therefore be used they must inform the user of solutions to day-to-day problems of clinical decision making.
3.2.
Our starting point, therefore, is to identify the processes of care through which a patient may pass (irrespective of judgements that might be made about them), to identify the decision nodes or branch-points between them and to identify the range of possible decisions that might be taken [8] . This will be the first task undertaken by the Specialty Working Groups (SWGs).
3.3.
The Clinical Audit Sub-Committee (COASC) has already conducted surveys of practice in lung and breast cancer [9] . Implicit in the design of these is the process of care as it is practised by oncologists; the responses obtained inform us of the likely variation in clinical practice and, therefore, of the different decisions that are likely to be taken. They begin to define the real problems that we intend to address.
3.4.
Having identified a number of critical decision nodes the literature concerned with these areas can then be identified. Unlike literature reviews it is essential to obtain all the literature relevant to a particular subject, even if experts are dismissive of its quality. It is well known, for example, that American authors writing literature reviews often omit most European papers from their studies. The absence of foreign language papers in UK articles also indicates selectivity. Of course, it is not always practical to access such information, particularly if there is no English abstract, but every effort to obtain all relevant information should be made. Indicates absence of directly applicable clinical studies of good quality 3.5. The studies collected must then be critically appraised [10] , analyzed for their information content and the evidence graded for quality. If there is considerable information available and the Cochrane Collaboration have no record of a systematic overview either conducted or planned, then this might trigger a request for one to be done. A meta-analysis could be performed immediately on the data already obtained and an overview could follow. The effort must be justified by the clinical importance of the judgement to be made. This will be the role of the COIN Cochrane Research Fellow post, enabling the process of assessing evidence to be accomplished entirely within the structure of the COIN project.
Guideline Construction
4.1.
Guideline development in oncology within the UK is very fragmented and guidelines are emerging from a wide variety of sources. In addition, the guidelines that are being issued appear in nonstandard formats and do not conform to criteria that have been advanced to define the composition of a good guideline. It is explicitly stated that such guidelines are not intended to prescribe the detailed management of individual patients.
The Royal
4.3.
Purchasers have been advised that clinical audit will be an important means of assessing the extent to which guidelines are used successfully in practice. An effective clinical audit programme will therefore need to be in place if guideline assessment is to be practicable.
4.4.
A subsequent executive letter from the NHS Executive (EL(94)74) [12] details further efforts to improve the clinical effectiveness of the NHS and describes efforts to survey guidelines work according to the above criteria; NHS endorsement is then given through the Clinical Outcomes Group (COG)
4.5.
In Scotland, the Clinical Resource and Audit Group (CRAG) has also produced a booklet about clinical guidelines [13] . They define clinical guidelines as 'systematically developed statements which assist in decision making about appropriate healthcare for specific clinical conditions'. They recommend that the term 'clinical guideline' should apply to the general statement of principle and that the word 'protocol' should cover the more detailed development of these broad principles for local application. The task of producing guidelines is in the hands of the Scottish Intercollegiate Guidelines Network (SIGN); the RCR representative on SIGN is Dr Grahame Howard (Edinburgh). There is at present no equivalent to SIGN in England.
4.6.
Unfortunately, COG has recently recommended that the term 'national clinical guideline' should apply to guidelines sponsored by the relevant professional bodies according a nationally agreed standard. The term 'local guideline' should apply to guidelines produced locally, which may or may not be based on national guidelines [14] . Therefore, the NHS in England is now using different definitions to the NHS in Scotland. However, they both believe that a multidisciplinary approach to the development and dissemination of guidelines and to the development of protocols is essential.
In Wales, there is a Welsh Clinical Effectiveness
Group to co-ordinate policy and resources, based at the Welsh Office.
CRAG recommends the following attributes
(taken from the AHCPR report) as a basis for assessing guidelines:
1. Validity: the guideline does what it is intended to do. 2. Reliability and reproducibility: implies that a doctor, following the guideline, would reach the same conclusion in a series of similar patients and that a number of doctors, using the guideline, would reach the same conclusion if faced with the same circumstances. 3. Clinical applicability: a statement of the population to which criteria apply. 4. Clinical flexibility: identification of acceptable departures from the recommendations of the guideline to allow for reasoned diversions in clinical judgement, patient preference, unique clinical situations or unusual features arising from, for example, an isolated location. 5. Clarity: a guideline should be easily comprehensible by those who are expected to use it. 6. Multidisciplinary process: the group developing the guideline should include representatives from all professions that might be involved in its implementation. 7. Scheduled review: evaluation, monitoring, revision and updating are essential to make sure that the guideline is and remains effective and efficient. The programme for review should be an integral part of the guideline, and this should include the method, frequency and agency responsible for ongoing management (comment -this is one of the major areas where the UK really falls down since there are no bodies charged with this responsibility and at present we would certainly regard ourselves, within the COIN Project, as the appropriate group to undertake this task for clinical oncology). 8. Documentation.
4.9.
Within the CRAG document there is some discussion of methodology. They do not recognize any single 'correct' way for producing a clinical guideline, but suggest it is likely that development will go through a number of stages: 1. Definition of the topic to be covered. We envisage that our specialty groups will need to be constituted on a semipermanent basis to ensure the regular review of guidelines in the light of new knowledge.
Connections
5.1.
As part of the setting up of our own guidelines project, we are establishing links with the other bodies in the UK who may be formulating national guidelines of their own. In the recent past, there have been several instances (regarded within our College with ominous misgivings) of the development of guidelines by outside agencies who wish to attempt to impose a standard of care on specialists in a given field. They embarked on their work, often with little or no professional input, but merely by reference to the published literature.
5.2.
More recently, ad hoc groups appear to be forming, this time composed of selected individuals. In many cases, however, it is unlikely that the product of their work will conform to the criteria outlined above as there is a general ignorance of these criteria, and once again it is unlikely that any mechanism for widespread consultation to provide a sense of ownership is possible. Nevertheless, they may provide a resource on which we can draw for our own work.
5.3.
We have made contact with the Cochrane Collaboration, the NHS Centre for Reviews and Dissemination and the UK Clearing House for Outcomes. We are also deeply involved with European Commission AIM projects currently being planned. The ECOLE (European Collaborative Oncology Literature Evaluation) project and GRIP (Guidelines and Recommendations databases for Implementing cancer research results into Practice) are complementary projects involving a core of five EU members including the UK. It is intended that they will provide both literature reviews and guidelines together with authoring tools and methods for accessing data online. They should provide a detailed pan-European perspective on colon cancer (the site that has been selected for initial development). If successful, this will open the door to pan-European collaboration on other cancer sites.
5.4.
The first fruit of the COIN Programme, Guidelines on the Non-Surgical Management of Lung Cancer, is published elsewhere in this issue of Clinical Oncology [15] ; it is planned to publish guidelines on breast, colorectal, prostate and testicular cancer and on generic aspects of radiotherapy and chemotherapy in Clinical Oncology during 1999.
Practicalities
6.1. The first stage is to establish for all cancer sites and processes of care appropriate SWGs. The COIN project has completed a survey that enables interested and suitable members to be identified for each SWG. The groups will be supported by the COIN project team and their expenses covered from within the COIN project. In addition, keen interest in the COIN project has been expressed by cancer nurses, therapy radiographers and radiotherapy physicists. It is important that managers and patient representatives are also included in the SWGs.
6.2.
The first version of the guidelines will be consensus rather than evidence-based guidelines, addressing the areas of maximum MPV. During the drafting period they will be circulated for wide discussion within the professional groups that will create them: clinical and medical oncologists, cancer nurses, therapy radiographers and radiotherapy physicists. Comments and criticisms will all be recorded and formally addressed but the aim will be to reach a definite consensus wherever feasible. 6.4. Version 2 will see the addition of the evidence supporting the guidelines, where it exists. It will need to be graded so that it is possible to see how reliable the evidence is on which decisions have been based. Following further wide consultation and debate, the guidelines documents will now contain a stated set of guidelines conforming to the specifications laid out above and supported by critically appraised literature.
6.5. It will then remain to create a mechanism to permit regular updating of guidelines, particularly as new evidence emerges but also if further critical appraisal suggests a different weighting for previously reviewed evidence (e.g. because of reanalysis of data because of fraud, which appears to be increasing) or because the results of a megatrial overrule the results of a meta-analysis (as has recently occurred with the use of magnesium in acute myocardial infarction) [16] .
6.6.
Critical appraisal is defined as 'the application of certain rules of evidence to clinical, epidemiological and other published data, in order to determine their validity and applicability'. North Thames Research Appraisal Group, funded by the North Thames R & D Directorate, have been running a series of workshops on critical appraisal. Their critical review forms for evaluation of economic studies, meta-analyses and systematic overviews and audit and guidelines are available from the COIN office. It is strongly recommended that they be adopted and modified for other types of scientific study. At least two identified individuals should critically review any given study and their assessments will form part of the guidelines database.
6.7. COIN intends that the UK RCR guidelines database will appear online as part of the World Wide Web; plans to create our own Web server are under development. In addition, they should also appear as part of GRIP on a server possibly within the UK NHS Nationwide Network and will also be distributed to all oncologists and interested parties within the UK on the COIN database.
7. Piloting 7.1. Small scale piloting of the finished guidelines will take place within one to three centres within a region (e.g. North Thames) followed by large scale piloting involving centres from several English regions. Separate arrangements will be made for piloting in the other countries of the UK.
Audit
8. 1 . In order to demonstrate that guidelines result in changes in practice it will be necessary to conduct baseline studies using COIN core data sets before the guidelines are adopted; the guidelines will need to be converted locally into protocols (or are they local guidelines?) in each centre and COIN will also need to conduct an audit of this process; local audit will then need to be conducted and the results collated in the COIN project office for the national audit of guideline compliance.
8.2.
No funding has yet been identified for the pilot and validation phases of the project; the RCR will rely on the NHSE to provide continued funding for the COIN project.
